KEYMED BIOSCIENCES -0001 Market Cap ($2.57 Billion)
Market Cap & Net Worth: KEYMED BIOSCIENCES -0001 (64Z)
KEYMED BIOSCIENCES -0001 market cap. KEYMED BIOSCIENCES -0001 (F:64Z) has a market capitalization of $2.57 Billion (€2.19 Billion) as of November 3, 2026. Listed on the F stock exchange, this Germany-based company holds position #5207 globally and #853 in its home market, demonstrating a -18.13% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying KEYMED BIOSCIENCES -0001's stock price €7.45 by its total outstanding shares 294599566 (294.60 Million). Also see cash flow conversion of KEYMED BIOSCIENCES -0001 for how efficiently the company converts equity into cash flow.
KEYMED BIOSCIENCES -0001 Market Cap History (2022–2026)
KEYMED BIOSCIENCES -0001 market cap history from 2022 to 2026. Data shows growth from $2.08 Billion to $2.57 Billion (27.62% CAGR). Check KEYMED BIOSCIENCES -0001 share price for real-time trading data and today's change.
KEYMED BIOSCIENCES -0001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how KEYMED BIOSCIENCES -0001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of KEYMED BIOSCIENCES -0001 to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
2.69x
KEYMED BIOSCIENCES -0001's market cap is 2.69 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $2.08 Billion | $100.06 Million | -$308.12 Million | 20.82x | N/A |
| 2023 | $1.88 Billion | $354.10 Million | -$359.36 Million | 5.30x | N/A |
| 2024 | $1.23 Billion | $428.12 Million | -$515.24 Million | 2.86x | N/A |
| 2025 | $1.93 Billion | $716.31 Million | -$522.64 Million | 2.69x | N/A |
Competitor Companies of 64Z by Market Capitalization
Companies near KEYMED BIOSCIENCES -0001 in the global market cap rankings as of November 3, 2026. Also see 64Z asset base for a full breakdown of the balance sheet.
Key companies related to KEYMED BIOSCIENCES -0001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of KEYMED BIOSCIENCES -0001 (2022–2026)
Market capitalization of KEYMED BIOSCIENCES -0001 from 2022 to today. Between 2022 and today, KEYMED BIOSCIENCES -0001's market cap moved from $2.08 Billion to $ 2.57 Billion, with a yearly change of 27.62%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €2.57 Billion | +33.04% |
| 2025 | €1.93 Billion | +57.30% |
| 2024 | €1.23 Billion | -34.68% |
| 2023 | €1.88 Billion | -9.92% |
| 2022 | €2.08 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of KEYMED BIOSCIENCES -0001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.57 Billion USD |
| MoneyControl | $2.57 Billion USD |
| MarketWatch | $2.57 Billion USD |
| marketcap.company | $2.57 Billion USD |
| Reuters | $2.57 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About KEYMED BIOSCIENCES -0001
Keymed Biosciences Inc., a biotechnology company, engages in the discovery and development of biological therapies in the autoimmune and oncology therapeutic areas in Mainland China, the United States, and the United Kingdom. The company develops Kangyueda for the treatment of moderate-to-severe atopic dermatitis in adults, chronic rhinosinusitis with nasal polyps, and seasonal allergic rhinitis;… Read more